1,538
Views
7
CrossRef citations to date
0
Altmetric
Articles

Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials

, &
Pages 157-172 | Received 21 Nov 2014, Accepted 06 Oct 2015, Published online: 16 Dec 2015

References

  • Appadurai, A. (1986) ‘Introduction: commodities and the politics of value’, in The Social Life of Things: Commodities in Cultural Perspective, ed A. Appadurai, Cambridge University Press, Cambridge, pp. 3–63.
  • Bowker, G. C. & Star, S. L. (1999) Sorting Things Out: Classification and Its Consequences, MIT Press, Cambridge, MA.
  • Callon, M. (Ed.) (1998) The Laws of the Markets, Blackwell, Oxford.
  • Callon, M., Millo, Y. & Muniesa, F. (Eds) (2007) Market Devices, Blackwell, Oxford.
  • Callon, M. & Muniesa, F. (2005) ‘Economic markets as calculative collective devices’, Organization Studies, vol. 26, pp. 1229–1250. doi: 10.1177/0170840605056393
  • Cochoy, F. (2008) ‘Calculation, qualculation, calqulation: shopping cart arithmetic, equipped cognition and the clustered consumer’, Marketing Theory, vol. 8, no. 1, pp. 15–44. doi: 10.1177/1470593107086483
  • Daston, L. & Galison, P. (1992) ‘The image of objectivity’, Representations, vol. 40, Autumn, pp. 81–128. doi: 10.1525/rep.1992.40.1.99p0137h
  • Dewey, J. (1939) Theory of Valuation, The University of Chicago Press, Chicago, IL.
  • Dickersin, K., Chan, S., Chalmersx, T. C., Sacks, H. S. & Smith Jr, H. (1987) ‘Publication bias and clinical trials’, Controlled Clinical Trials, vol. 8, no. 4, pp. 343–353. doi: 10.1016/0197-2456(87)90155-3
  • Dussauge, I., Helgesson, C.-F. & Lee, F. (2015) ‘Valuography: studying the making of values’, in Value Practices in the Life Sciences and Medicine, eds I. Dussauge, C.-F. Helgesson & F. Lee, Oxford University Press, Oxford, pp. 267–285.
  • Epstein, S. (1996) Impure Science: AIDS, Activism, and the Politics of Knowledge, University of California Press, Berkeley.
  • Fisher, L. D. (1999) ‘Advances in clinical trials in the twentieth century’, Annual Review of Public Health, vol. 20, pp. 109–124. doi: 10.1146/annurev.publhealth.20.1.109
  • Fisher, J. A. (2009) Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials, Rutgers University Press, New Brunswick, NJ.
  • Fleck, L. (1979) Genesis and Development of a Scientific Fact, University of Chicago Press, Chicago, IL.
  • Fujimura, J. H. (1987) ‘Constructing ‘do-able’ problems in cancer research: articulating alignment’, Social Studies of Science, vol. 17, no. 2, pp. 257–293. doi: 10.1177/030631287017002003
  • Fujimura, J. H. (2013) Confounded Categories: Is the HapMap a Race-based Project? 4S/EASST Design and Displacement – Social Studies of Science and Technology, Copenhagen.
  • Hackshaw, A. (2009) A Concise Guide to Clinical Trials, Wiley-Blackwell, Chichester.
  • Haraway, D. J. (1988) ‘Situated knowledges: the science question in feminism and the privilege of partial perspective’, Feminist Studies, vol. 14, no. 3, pp. 575–599. doi: 10.2307/3178066
  • Harding, S. (1991) ‘Feminist standpoint epistemology’, in The Gender and Science Reader, eds I. Bartsch & M. Lederman, Routledge, London, pp. 145–168.
  • Helgesson, C.-F. (2010) ‘From dirty data to credible scientific evidence: some practices used to clean data in large randomised clinical trials’, in Medical Proofs, Social Experiments: Clinical Trials in Context, eds C. Will & T. Moreira, Ashgate, Aldershot, pp. 49–66.
  • Helgesson, C.-F. & Kjellberg, H. (2013) ‘Values and valuations in market practice’, Journal of Cultural Economy, vol. 6, no. 4, pp. 361–369. doi: 10.1080/17530350.2013.838187
  • Helgesson, C.-F. & Muniesa, F. (2013) ‘For what it's worth: an introduction to valuation studies’, Valuation Studies, vol. 1, no. 1, pp. 1–10. doi: 10.3384/vs.2001-5992.13111
  • Heuts, F. & Mol, A. (2013) ‘What is a good tomato? A case of valuing in practice’, Valuation Studies, vol. 1, no. 2, pp. 125–146. doi: 10.3384/vs.2001-5992.1312125
  • Jonvallen, P. (2005) Testing Pills, Enacting Obesity: The Work of Localizing Tools in a Clinical Trial, Published PhD Diss., Department of Thematic Studies – Technology and Social Change, Linköping University.
  • Keating, P. & Cambrosio, A. (2006) Biomedical Platforms: Realigning the Normal and the Pathological in Late-Twentieth-Century Medicine, MIT Press, Cambridge.
  • Kjellberg, H., Mallard, A., Arjaliès, D.-L., Aspers, P., Beljean, S., Bidet, A., Corsin, A., Didier, E., Fourcade, M., Geiger, S., Hoeyer, K., Lamont, M., MacKenzie, D., Maurer, B., Mouritsen, J., Sjögren, E., Tryggestad, K., Vatin, F. & Woolgar, S. (2013) ‘Valuation studies? Our collective two cents’, Valuation Studies, vol. 1, no. 1, pp. 11–30. doi: 10.3384/vs.2001-5992.131111
  • Lai, T. L., Lavori, P. W., Shih, M. C. I. & Sikic, B. I. (2012) ‘Clinical trial designs for testing biomarker-based personalized therapies’, Clinical Trials, vol. 9, no. 2, pp. 141–154. doi: 10.1177/1740774512437252
  • Latour, B. (2005) Reassembling the Social: An Introduction to Actor-Network-Theory, Oxford University Press, Oxford.
  • Löwy, I. (1996) Between Bench and Bedside: Science, Healing, and Interleukin-2 in a Cancer Ward, Harvard University Press, Cambridge.
  • Machin, D. & Campbell, M. J. (2005) Design of Studies for Medical Research, Wiley, Hoboken, NJ.
  • Machin, D. & Fayers, P. M. (2010) Randomized Clinical Trials: Design, Practice, and Reporting, John Wiley & Sons, Chichester.
  • MacKenzie, D. (1999) ‘Nuclear missile testing and the social construction of accuracy’, in The Science Studies Reader, ed Mario Biagioli, Routledge, New York and London, pp. 342–357.
  • MacKenzie, D. (2009) Material Markets: How Economic Agents Are Constructed, Oxford University Press, Oxford.
  • MacKenzie, D. & Millo, Y. (2003) ‘Constructing a market, performing theory: the historical sociology of a financial derivatives exchange’, American Journal of Sociology, vol. 109, no. 1, pp. 107–145. doi: 10.1086/374404
  • MacKenzie, D., Muniesa, F. & Siu, L. (Eds) (2007) Do Economists Make Markets? On the Performativity of Economics, Princeton University Press, Princeton, NJ.
  • Mandrekar, S. J. & Sargent, D. J. (2009) ‘Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges’, Journal of Clinical Oncology, vol. 27, no. 24, pp. 4027–4034. doi: 10.1200/JCO.2009.22.3701
  • Marks, H. M. (1997) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990, Cambridge University Press, Cambridge.
  • Metzler, I. (2010) ‘Biomarkers and their consequences for the biomedical profession: a social science perspective’, Personalized Medicine, vol. 7, no. 4, pp. 407–420. doi: 10.2217/pme.10.41
  • Mitchell, R. & Waldby, C. (2010) ‘National biobanks: clinical labor, risk production, and the creation of biovalue’, Science, Technology & Human Values, vol. 35, no. 3, pp. 330–355. doi: 10.1177/0162243909340267
  • Mol, A. (1999) ‘Ontological politics: a word and some questions’, in Actor-Network Theory and After, eds J. Law & J. Hassard. Blackwell, Oxford, pp. 74–89.
  • Muniesa, F. (2012) ‘A flank movement in the understanding of valuation’, in Measure and Value, eds L. Adkins & C. Lury. Wiley-Blackwell, Oxford, pp. 24–38.
  • Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for Human Subjects, Princeton University Press, Princeton, NJ.
  • Porter, T. M. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life, Princeton University Press, Princeton, NJ.
  • Rose, N. (2007) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-first Century, Princeton UP, Princeton, NJ.
  • Shiva, V. (1997) Biopiracy: The Plunder of Nature and Knowledge, South End Press, Boston, MA.
  • Sismondo, S. (2009) ‘Ghosts in the machine: publication planning in the medical sciences’, Social Studies of Science, vol. 39, no. 2, pp. 171–198. doi: 10.1177/0306312708101047
  • Sjögren, E. & Helgesson, C.-F. (2007) ‘The Q(u)ALYfying hand: health economics and medicine in the shaping of Swedish markets for subsidised pharmaceuticals’, in Market Devices, eds M. Callon, Y. Millo & F. Muniesa. Blackwell, Oxford, pp. 215–240.
  • Skærbæk, P. & Tryggestad, K. (2010) ‘The role of accounting devices in performing corporate strategy’, Accounting, Organizations and Society, vol. 35, no. 1, pp. 108–124. doi: 10.1016/j.aos.2009.01.003
  • Stark, D. (2000) For a Sociology of Worth. Working Paper Series, Center on Organizational Innovation, Columbia University.
  • Stark, D. (2009) The Sense of Dissonance: Accounts of Worth in Economic Life, Princeton University Press, Princeton, NJ.
  • Sunder Rajan, K. (2006) Biocapital: The Constitution of Postgenomic Life, Duke University Press, Durham, NC.
  • Waldby, C. (2002) ‘Stem cells, tissue cultures and the production of biovalue’, Health, vol. 6, no. 3, pp. 305–323.
  • Will, C. & Moreira, T. (Eds) (2010) Medical Proofs, Social Experiments: Clinical Trials in Context, Ashgate, Aldershot.
  • Winner, L. (1980) ‘Do artifacts have politics?’ Daedaleus, vol. 109, no. 1, pp. 121–136.
  • Wise, M. N. (1995) ‘Introduction’, in The Values of Precision, ed M. N. Wise, Princeton University Press, Princeton, NJ, pp. 3–13.
  • Zelizer, V. A. (1985) Pricing the Priceless Child: The Changing Social Value of Children, Basic Books, New York.
  • Zelizer, V. A. (2005) The Purchase of Intimacy, Princeton University Press, Princeton, NJ.